The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain.

@article{Costa2007TheNC,
  title={The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain.},
  author={B{\'a}rbara Costa and Anna Elisa Trovato and Francesca Comelli and Gabriella Giagnoni and Mariapia Colleoni},
  journal={European journal of pharmacology},
  year={2007},
  volume={556 1-3},
  pages={
          75-83
        }
}
Cannabidiol, the major psycho-inactive component of cannabis, has substantial anti-inflammatory and immunomodulatory effects. [...] Key Result In the neuropathic animals, the anti-hyperalgesic effect of cannabidiol (20 mg/kg) was prevented by the vanilloid antagonist capsazepine (10 mg/kg, i.p.), but not by cannabinoid receptor antagonists.Expand
Cannabis constituent synergy in a mouse neuropathic pain model
TLDR
It is demonstrated that CBD synergistically enhances the pain-relieving actions of THC in an animal neuropathic pain model, but has little impact on the THC-induced side effects, which suggests that low dose THC:CBD combination treatment has potential in the treatment of neuropathicPain. Expand
Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain
TLDR
Results suggest that THC may be more beneficial than CBD for reducing inflammatory pain in that THC maintains its efficacy with short-term treatment in both sexes and does not induce immune activation. Expand
Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination
TLDR
Specific immune cell markers associated with T cell differentiation and pro-inflammatory cytokines, previously implicated in repair processes, were differentially up-regulated by cannabinoids in males treated with cannabinoids, but not in females, warranting further investigation into sexual dimorphisms that may underlie treatment outcomes. Expand
Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model
TLDR
It is demonstrated that oral THC and CBD, alone and in combination, have analgesic efficacy in an animal neuropathic pain model and both THC and combination THC:CBD display a relatively poor therapeutic window when delivered orally, which suggests that CBD provides a safer, albeit lower efficacy, oral treatment than THC-containing preparations. Expand
Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved
TLDR
It was found that a controlled cannabis extract, containing multiple cannabinoids, in a defined ratio, and other non‐cannabinoid fractions (terpenes and flavonoids) provided better antinociceptive efficacy than the single cannabinoid given alone, when tested in a rat model of neuropathic pain. Expand
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
TLDR
Cannabidiol, a likely safe compound, prevents experimental colitis in mice and reduces colon injury and endocannabinoid changes associated with 2,4,6-dinitrobenzene sulfonic acid administration. Expand
Progress in study of Cannabis sativa leaves extracts without psychotropic cannabinoids in animal model of neuropathic pain
TLDR
The present review addresses the recent advances in the study of pharmacological mechanisms on cellular and receptor level underlying non-hallucinogenic cannabinoid analgesic effect. Expand
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
TLDR
The basic research regarding molecular mechanism of CBD’s action is reviewed with particular focus on its analgesic potential, and the detailed analgesic and anti-inflammatory effects of CBD in various models, including neuropathic pain, inflammatory pain, osteoarthritis and others are described. Expand
Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative
TLDR
Findings show that HUF-101 produced antinociceptive effects at lower doses than CBD, indicating that the addition of fluoride improved its pharmacological profile. Expand
Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice
TLDR
The data of this study indicate that in addition to intraperitoneal application, intrarectal delivery of cannabinoids may represent a useful therapeutic administration route for the treatment of colonic inflammation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw
TLDR
Oral cannabidiol has a beneficial action on two symptoms of established inflammation: edema and hyperalgesia and the effect on NO seemed to depend on a lower expression of the endothelial isoform of NO synthase. Expand
A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
TLDR
The hypothesis that the combination of THC and CBD increases clinical efficacy while reducing adverse events is supported, and prospects for future application of whole cannabis extracts in neuroprotection, drug dependency, and neoplastic disorders are examined. Expand
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
TLDR
Data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA. Expand
Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve
TLDR
The present findings suggest that SR141716 is effective not only in alleviating neuropathic pain but also in favouring the nerve myelin repair and consequently promote long‐lasting functional recovery. Expand
The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
TLDR
The data indicate that cannabinoids may have therapeutic potential in neuropathic pain, and that this effect is mediated through the CB1 receptor. Expand
Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat
TLDR
A role for CB‐2 receptor‐mediated antinociception in both acute and neuropathic pain in addition to centrally located CB‐1 mechanisms is suggested. Expand
Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain
TLDR
Coadministration of a low dose of morphine, but not cannabidiol, with Δ9‐THC, increased antinociception and 5‐hydroxytryptamine levels in the thalamus in a model of persistent nociceptive effects. Expand
Antinociceptive activity of ricinoleic acid, a capsaicin-like compound devoid of pungent properties.
TLDR
Ricinoleic acid seems to be a new antinociceptive agent lacking the pungent and acute hyperalgesic properties of capsaicin. Expand
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.
TLDR
Cannabidiol was more protective against glutamate neurotoxicity than either ascorbate or alpha-tocopherol, indicating it to be a potent antioxidant, and data suggest that the naturally occurring, nonpsychotropic cannabinoid, cannABidiol, may be a potentially useful therapeutic agent for the treatment of oxidative neurological disorders such as cerebral ischemia. Expand
Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo‐oxygenase systems
TLDR
It is shown, for the first time, that palmitoylethanolamide has a curative effect in a model of acute inflammation, inhibiting the carrageenan‐induced oedema in a dose‐ and time‐dependent manner. Expand
...
1
2
3
4
5
...